-
FDA approves Galderma's Mirvaso for redness of rosacea
FORT WORTH, Texas — The Food and Drug Administration has approved a drug made by Galderma Labs for treating a side effect of rosacea in adults, the company said.
Galderma announced the approval of Mirvaso (brimonidine) topical gel in the 0.33% strength for the topical treatment of facial erythema of rosacea. The drug is applied once per day to reduce redness and lasts up to 12 hours. The company expects the drug to become available in pharmacies next month.
-
ScriptPro to use biometric authentication systems from Xelios
MISSION, Kan. — The pharmacy automation and management systems made by ScriptPro will begin using biometric authentication technology from Xelios Biometrics, under a multi-year licensing agreement between the two companies.
The companies said such biometric identifiers as fingerprints would be more reliable in verifying identity than identification cards or personal identification numbers, which are currently used in ScriptPro's systems. Financial terms of the deal were not disclosed.